Phase 2 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 to 75 years old
- People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer), either through clinical assessment or tissue testing
- People whose liver cancer cannot be removed by surgery, has spread to nearby areas, or has spread to other parts of the body
- People who have already received at least two different treatment regimens for their cancer, including both a targeted therapy and an immune checkpoint inhibitor (a type of immunotherapy)
- People whose most recent two-drug treatment showed some benefit — meaning the cancer shrank or stayed stable for at least 4 weeks — before the cancer started growing again or the treatment stopped working
- People who have at least one tumour that can be measured on a scan, according to standard measurement guidelines
- People whose overall health and ability to carry out daily activities is rated as good to fully active (a score of 0 or 1 on a standard scale used by doctors)
- People whose blood counts, kidney function, and liver function meet the specific levels required by the trial (confirm with trial site)
- People whose hepatitis B and hepatitis C status has been tested; those with hepatitis B may still be considered if they receive appropriate antiviral treatment as recommended by a liver specialist
Who may not be able to join:
- People whose cancer showed no benefit at all from their most recent treatment and progressed quickly within 6 weeks or 2 treatment cycles
- People who have previously been treated with lenalidomide, or who have had a serious allergic reaction to lenalidomide or a related drug called thalidomide
- People whose cancer is progressing very rapidly, or where a doctor has determined it is no longer reasonable to continue on the current treatment approach
- People with uncontrolled fluid build-up in the abdomen, confusion caused by liver failure, active bleeding in the digestive tract, or serious uncontrolled infections (including uncontrolled hepatitis B, tuberculosis, or severe lung infections)
- People who still have ongoing side effects from previous treatments that have not returned to an acceptable level before starting the trial
- People whose kidney function falls below the minimum level required (confirm specific threshold with trial site)
- People who are pregnant, breastfeeding, or who are unable or unwilling to follow the contraception requirements of the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 010-69156874
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Grade ≥3 Treatment-Related Adverse Events; 6-Month Progression-Free Survival Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.